Purpose: Treatment with hematopoietic growth factors increases the percentage of hematopoietic progenitor cells in cell cycle. Following withdrawal of certain growth factors, preclinical data suggest that there is a transient fall in the percentage of progenitor cells in cycle below the baseline, thus providing a window to administer chemotherapy with reduced risk of myelotoxicity.
INTRODUCTION
Cancer cell resistance to DNA damaging agents can be overcome by increasing the dose intensity [1] . This observation has provided the rationale for the use of high dose chemotherapy combined with growth factors, with or without autologous blood progenitor cell rescue. Studies to date have shown that colony stimulating factors (CSFs)e decrease the duration of myelosuppression and its associated morbidity [2, 3] . CSFs aTo whom all correspondence should be addressed: John R. Murren hours [4] . In a larger group of patients, Vadhan-Raj, Broxmeyer and colleagues confirmed these findings for GM-CSF and reported similar results with pIXY321, but not with G-CSF [5] [6] [7] . These observations suggested that a priming schedule of certain growth factors, coupled with the appropriate rest period before the administration of chemotherapy, might reduce the percentage of marrow progenitor cells in cycle at the time the chemotherapy is given and thus render the bone marrow less susceptible to chemotherapy induced toxicity. pIXY 321 is a recombinant protein that contains both IL-3 and GM-CSF domains [5, [8] [9] [10] . pIXY 321 produced significantly enhanced biological effect in vitro on both myeloand thrombopoiesis, perhaps by multiple cross linking of GM-CSF, IL-3 and dual receptors [11, 12] . In clinical trials, pIXY 321 has been well tolerated with the most common reported side-effect being erythema at the injection site and mild constitutional symptoms.
There appears to be a dose response effect at doses less than 1000 Vg/m2/day [13] . Some studies have shown a biological effect at a dose of 125 ,ug/m2/day, though in others a dose of 500-750 ,ug/m2/day was necessary. The optimal biologic dose appears to be 375 pg/m2/day administered twice daily [13] .
The combination of the DNA damaging agents ifosfamide, etoposide and a platinum analog ("ICE") has demonstrated significant activity in lung cancer, germ cell tumors, lymphomas and pediatric malignancies [14] [15] [16] [17] [18] [19] [20] . The major dose limiting toxicity of this drug combination is myelosuppression, and significant dose escalation is feasible with the use of bone marrow rescue or the addition of cytokines. For example, Tepler and colleagues found that a 25 percent increase in the dose intensity of carboplatin was feasible when G-CSF was incorporated into the ICE regimen [19] . Furthermore, they reported that when IL-3 was given in combination with G-CSF following this chemotherapy regimen, the degree and duration of the myelosuppression was further reduced, suggesting that there was synergy between G-or GM-CSF and IL-3.
Based on these data, we designed a study to measure the effects of a priming schedule of pIXY321 on hematopoietic progenitor cell kinetics and assess whether priming reduced the myelotoxicity anticipated with ICE chemotherapy.
PATIENTS AND METHODS

Eligibility
Patients with biopsy-proven, previously untreated solid tumors were eligible to participate in this study. All 
Dosages and drug administration
The pIXY321 was administered at a dose of 375 pg/m2 given subcutaneously twice daily. The priming dose was delivered over seven days followed by a two-day rest before the start of the chemotherapy. The pIXY321 was resumed at the same dose 24 hours after the completion of chemotherapy (day 4) and was continued for 10 consecutive days or until the WBC exceeded 15,000/p1 and the platelet count exceeded 100,0004i1.
Premedication for the chemotherapy consisted of 20 mg of ondansetron or 0.1 mg/kg of granisetron admixed with 10 mg of dexamethasone. The antiemetics were repeated every eight to 12 hours as needed. Mesna at a dose of 400 mg/M2 was infused just before and then four, eight and 12 hours after the ifosfamide. The final two doses of mesna were sometimes given orally by diluting 800 mg/m2/dose of mesna in juice. Ifosfamide at a dose of 2 gmlm2/d, and etoposide at a dose of 75 mg/m2/d, were given intravenously on days 1 to 3 of each chemotherapy cycle. Carboplatin was administered at a dose of 400 mg/M2 on day 1 only of each cycle.
Chemotherapy was repeated every three weeks provided that there was hematologic recovery (absolute neutrophil count >I500/pl and platelet >100,0004s1), complete resolution of mucositis and diarrhea, no evidence of gross hematuria, and no other serious nonhematologic toxicity. The doses of all chemotherapy drugs were calculated according to the patient's actual body weight, unless the body weight was more than 30 percent of the ideal weight. In this situation, the ideal weight plus 30 percent was used to calculate doses. Dose reduction of 25 percent was permitted on subsequent chemotherapy cycles for grade 3 nonhematologic toxicities, neutropenic fever with documented infection and a nadir platelet count of <20,000/4t. pIXY321 was supplied by the Immunex Corp (Seattle, WA) in 1.5 mg vials and was reconstituted in 1 ml of bacteriostatic water. For some patients who experienced injection site reactions, 1 mg of hydrocortisone sodium phosphate was injected into the pIXY321 vial before reconstitution. On-study examinations and criteria for assessment of response and toxicity A history including assessment of performance status, physical examination, a complete blood count, electrolytes, BUN, creatinine, creatinine clearance, liver function tests (aspartate aminotransferase, lactate dehydrogenase, total and direct bilirubin, alkaline phosphatase), serum calcium and phosphate, total protein, albumin, prothrombin time, urinalysis, pregnancy test (if indicated), chest radiograph and computed tomography scans (if appropriate for staging the disease) were obtained prior to the start of treatment. A physical examination and toxicity assessment were repeated weekly. Toxicity was graded according to the National Cancer Institute common toxicity criteria. A complete blood count and differential were obtained every two to three days while the patients were receiving the pIXY321. The complete blood count and a chemistry profile was repeated before every treatment cycle. Formal tumor measurements were obtained after every two cycles of chemotherapy. Response duration was measured from the time of first documented response until progression. Survival was measured from the time of entry on study and estimated using the Kaplan-Meier method. Analysis of hematopoietic progenitor cell kinetics On days -8 and -2 (the start and completion of the priming schedule of pIXY321) and day 1 of chemotherapy during first and second cycles, 15 ml of blood was obtained in anticoagulated tubes. Blood samples from patients treated at the Cancer Institute of New Jersey and at affiliated hospitals were shipped by overnight courier mail. Mononuclear cells were isolated from the blood samples by centrifugation through a ficoll-Hypaque density gradient. The mononuclear cells were washed, treated with RNase A, incubated with a fluorocein-conjugated anti-CD34 monoclonal antibody and then stained with propidium iodide. The samples were analyzed in a flow cytometer, and the cell cycle distribution in the CD34 cell population was determined.
RESULTS
Twenty patients were entered into the study and received a total of 54 cycles (Table  1) . Four patients experienced allergic reactions from pIXY321 and were removed from the study prior to the administration of chemotherapy. An additional two patients withdrew following the first cycle of chemotherapy due to unacceptable side effects (1) (Table 2) . Non-hematologic toxicities The most common non-hematological toxicities were mild fatigue and weight loss, which were observed in 11 of 19 patients. Two patients developed mental status changes during chemotherapy, which were attributed to the ifosfamide, and the patients had chemotherapy discontinued after three cycles and two cycles, respectively. Gastrointestinal side effects were uncommon, and consisted of mild stomatitis (1) and diarrhea (2) .
Local erythema and edema at the site of the pIXY injection was seen in seven patients. Four of these patients experienced grade 2 erythema/edema at the site of injection, and an additional patient experienced grade 2 nausea/vomiting after the pIXY321 was administered. In two patients, hydrocortisone was mixed with the pIXY321 before injection, and this reduced the severity of the local irritation. In an additional four patients, however, allergic reactions were severe and precluded further participation in the study. Three of these patients developed symptoms following the first or second injection of pIXY321 consisting of sneezing, tongue swelling, difficulty swallowing, facial flushing, drooling, chest pressure and dyspnea. The fourth patient experienced respiratory distress and flushing following the first cycle of therapy.
Three thrombotic events occurred in patients in this study. One patient experienced a myocardial infarction and cardiac arrest after the second cycle of chemotherapy. This patient had no prior anginal syndrome and had a hemoglobin of 8.9 g/dl at the time of the infarct. Two patients had documented deep venous thromboses. All three of these patients had carcinoma of the lung and may have had activation of coagulation pathways prior to the initiation of therapy. Progenitor cell cycle kinetics In five patients, there were insufficient numbers of progenitor cells detected in the peripheral blood to determine cell cycle distribution at baseline. In the fifteen patients in whom flow cytometric data are available, the average percentage of peripheral cells in S+G2/M was 9.6 percent. As shown in Figure 1 DISCUSSION Although most clinical trials have reported that pIXY321 is well tolerated, the frequency of certain non-hematologic toxicities in this study was notable. Four patients (20 percent) had allergic reactions severe enough to preclude continued treatment on the study. This is higher than the incidence of severe allergic reactions reported in other studies of pIXY321 and much higher than the incidence observed with either GM-CSF or G-CSF. Three of the 20 patients experienced thrombotic events. Proposed mechanisms by which these cytokines may contribute to hypercoagulability include induction of adhesion molecule expression on neutrophils and enhancement of platelet aggregation [21] [22] [23] . In a recent meta-analysis, the incidence of thrombotic events among patients receiving GM-CSF was 6.6 percent compared with 3.6 percent in controls, with an odds ratio of 1.67 (p >.05) [24] . An unexpectedly high incidence of thrombotic events has not been previously reported with pIXY321 and may reflect selection in this small patient cohort. If pIXY321 is further developed, however, additional investigation into its thrombogenic potential should be performed.
Some previous studies have suggested that certain cytokines given prior to the administration of chemotherapy decrease the percentage of progenitor cells in cycle, thus making the bone marrow protentially more resistant to the myelosuppressive effects of chemotherapy (Table 3) . For example, an Italian group found differences in the kinetic effects induced by GM-and G-CSF [25] . They reported that the bromodeoxyuridine (BUDR) labeling index in CD34+ marrow cells fell significantly below baseline two days after stopping GM-CSF but was still elevated two to four days after stopping G-CSF. Differences in these observed kinetic effects may be related to the population of cells expanded by a particular growth factor. Expansion of more primitive cell compartments might be necessary to affect feedback loops regulating hematopoiesis [26] and may contribute to the variable results summarized in Table 4 . In addition to the growth factor and the schedule, the results observed in Table 4 may also be related to biologic differences between CD34+ progenitor cells obtained in the peripheral blood and CD34+ progenitor cells residing in the marrow [27] . Although Paccagnella et al. reported that priming produced comparable results on the kinetics of these two cell populations [28] , in a limited number of samples using different assay techniques we found poor agreement between the priming effects on marrow and peripheral blood progenitor cells. Future studies should analyze marrow samples until effective priming schedules are defined and subsequently correlated with kinetics in peripheral progenitor cells.
Evaluation of a priming schedule of growth factor administration as a means of reducing myelotoxicity has been clinically tested in a limited number of patients. Aglietta et al. demonstrated reduced myelotoxicity in a small group of patients randomized to treatment with a priming schedule of GM-CSF [29] . In this study, none of the patients received growth factor support following chemotherapy. Janick et al. treated 24 evaluable patients [35] [36] CEF/CMF = cyclophosphamide, epirubicin, 5-fluorouacil alternating with cyclophosphamide, methotrexate, 5-fluorouacil; C/E/Ctx = carboplatin, etoposide, cyclophosphamide; P/E/E = cisplatin, epirubicin, etoposide; CyADIC = cyclophosphamide, doxorubicin, dacarbazine; HDCE = high-dose cyclophosphamide, etoposide, cisplatin; PBSC = peripheral blood stem cells; CDD = cisplatin. aDays on = no. of days priming growth factor given; days off = no. of days before start of chemo. bPatients receiving priming schedule/total patients treated in study. [28] [33]
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G-CSF/8d/2d G-CSF/5d/2d with topotecan followed by seven days of GM-CSF [30] . Half of the patients were randomized to also receive a five-day priming course of GM [31] .
The clinical efficacy observed by Janik et al. may be in part related to the use of a cycle-specific chemotherapy regimen. In a murine model, de Haan et al. recently demonstrated that the combination of stem cell factor and IL-I1 given for seven days followed by a one day rest before cycle-specific chemotherapy (5-fluorouracil) reduced the percentage of progenitor cells in cycle at the time of chemotherapy, and protected the animals from treatment-related toxicity [26] . In contrast to alkylating drugs, the cytotoxicity of the camptothecins is highly dependent on cells transversing the cell cycle. Since the dose limiting toxicity of this class of agents is myelosuppression, they are uniquely suited for evaluation of priming schedules designed to reduce the percentage of marrow progenitor cells in cycle. Therefore, future studies that test priming schedules of cytokines such as GM-CSF should be designed utilizing cycle-specific agents such as the camptothecins.
